Cipla to distribute Antibody Cocktail (Casirivimab and Imdevimab) in India

Used in treatment of mild to moderate Covid-19 in adults and pediatric patients (12 years and older)Roche India and Cipla today announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June.
In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients. Cipla will distribute the prodmidluct by leveraging its strong distribution strengths across the country. The drug will be available through leading hospitals and COVID treatment centers.
The Central Drugs Standards Control Organisation (CDSCO) had recently provided an Emergency Use Authorisation (EUA) for the antibody

Related Keywords

India , ,Central Drugs Standards Control Organisation ,Cipla ,Roche India ,Antibody Cocktail ,Emergency Use Authorisation ,Capital Market ,Drugs ,Health ,Covid 19 ,Occupational Safety And Health ,Public Health ,Zoonoses ,Antiviral Drugs ,Covid 19 Drug Development ,Treatment And Management Of Covid 19 ,Sofosbuvir Velpatasvir ,Harmaceuticals Nec ,Central Drugs Standards Control ,இந்தியா ,மைய மருந்துகள் தரநிலைகள் கட்டுப்பாடு ஆர்கநைஸேஶந் ,சிப்லா ,ரோச் இந்தியா ,ஆன்டிபாடி காக்டெய்ல் ,மூலதனம் சந்தை ,மருந்துகள் ,விட் ,